ImmunityBio, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 44.21 million compared to USD 16.52 million a year ago. Net loss was USD 632.78 million compared to USD 129.65 million a year ago.
Basic loss per share from continuing operations was USD 0.62 compared to USD 0.15 a year ago.

















